S216: CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDY

S216: CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDY

Bibliographic Details
Main Authors:	Huilai Zhang, Jingwei Yu, He LI, Wenbin Qian, Xibin Xiao, Qingqing Cai, Yao Liu, Yu Zhang, Liling Zhang, Ling Qin, Hui Zhou, Xiaoyi Tang, Yingmei Guo, Ting Niu
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000967776.81028.41

Similar Items

The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
by: Tianye Li, et al.
Published: (2024-03-01)

A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity
by: Diana I. Albu, et al.
Published: (2024-12-01)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
by: Bogang Wu, et al.
Published: (2018-11-01)

Progress of research on PD-1/PD-L1 in leukemia
by: Huizhen Cao, et al.
Published: (2023-09-01)

Towards the Application of a Label-Free Approach for Anti-CD47/PD-L1 Bispecific Antibody Discovery
by: Artem S. Grevtsev, et al.
Published: (2023-12-01)

Tumor‐derived exosomal PD-L1: a new perspective in PD-1/PD-L1 therapy for lung cancer
by: Yunjiao Wu, et al.
Published: (2024-03-01)

Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
by: Chaoyue Su, et al.
Published: (2020-09-01)

Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies
by: Hui Tang, et al.
Published: (2022-05-01)

Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
by: Tianye Li, et al.
Published: (2023-07-01)

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity
by: Haiping Jiang, et al.
Published: (2021-01-01)

Role of regulation of PD-1 and PD-L1 expression in sepsis
by: Teng Zhang, et al.
Published: (2023-03-01)

نقش PD-1/ PD-L1 و Anti-PD-1/ PD-L1 در پیشرفت و سرکوب سرطان
by: نرگس عبدالهی, et al.
Published: (2023-11-01)

Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy
by: Shengzhe Jin, et al.
Published: (2024-03-01)

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
by: Ke Zhang, et al.
Published: (2022-03-01)

Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer
by: Di ZHANG, et al.
Published: (2019-06-01)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
by: Jinhua Liu, et al.
Published: (2021-09-01)

Research progress of oncolytic virus combined with PD-1/PD-L1 inhibitors
by: GAN Zi-ying, TANG Hui
Published: (2022-04-01)

Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity
by: Shahram Salek-Ardakani, et al.
Published: (2021-10-01)

The significance of PD-1/PD-L1 imbalance in ulcerative colitis
by: Wei Shi, et al.
Published: (2023-05-01)

Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity
by: Zhenwei Zhong, et al.
Published: (2022-10-01)

The PD-1/PD-L1 Axis in the Biology of MASLD
by: Rosaria Maria Pipitone, et al.
Published: (2024-03-01)

PD-1/PD-L1 axis in organ fibrosis
by: Youliang Zhao, et al.
Published: (2023-05-01)

The PD-1:PD-L1 axis in Inflammatory Arthritis
by: Mary Canavan, et al.
Published: (2021-01-01)

Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells
by: Yunlong Zhao, et al.
Published: (2018-07-01)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
by: Ana Bocanegra, et al.
Published: (2020-08-01)

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
by: Xuan Zhao, et al.
Published: (2022-08-01)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
by: Mengke Niu, et al.
Published: (2022-03-01)

Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review
by: Yiru Zhang, et al.
Published: (2023-01-01)

Downregulation of Immunosuppressive Molecules, PD-1 and PD-L1 but not PD-L2, in the Patients with Multiple Sclerosis
by: Mohammad Reza Javan, et al.
Published: (2016-08-01)

272 PD-L1 CAR engineered K-NK cells to target PD-L1+ or PD-L1- tumors
by: Pedro Romero, et al.
Published: (2023-11-01)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
by: Xin Wang, et al.
Published: (2019-02-01)

Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo
by: Xiaoqiang Liu, et al.
Published: (2019-12-01)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
by: Yiru Long, et al.
Published: (2022-05-01)

PD-L1: expression regulation
by: Yu-Jie Zhou, et al.
Published: (2023-04-01)

Expression and Clinical Significance of PD-1 and PD-L1 in Pulmonary Carcinoids
by: Mingbiao LI, et al.
Published: (2016-12-01)

The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
by: Weiting Qin, et al.
Published: (2019-10-01)

Virtual Screening and In Vitro Evaluation of PD-L1 Dimer Stabilizers for Uncoupling PD-1/PD-L1 Interaction from Natural Products
by: Jrhau Lung, et al.
Published: (2020-11-01)

Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors
by: YU Lin, et al.
Published: (2021-08-01)

Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL
by: Tingting Zhang, et al.
Published: (2022-04-01)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
by: Hyun Tae Lee, et al.
Published: (2017-07-01)